HC Wainwright Affirms Alkermes (ALKS) ‘Neutral’ Rating on Vibrance-1 Phase 2 Study

Group 1 - Alkermes is recognized as one of the best beginner stocks to buy, with a 'Neutral' rating and a $46 price target from HC Wainwright following positive results from the Vibrance-1 phase 2 study [1][2] - The Vibrance-1 study results indicate that Alixorexton is the first orexin 2 receptor agonist to show a clinically meaningful and statistically significant impact on wakefulness, cognition, and fatigue [2][3] - Improvements in patient-reported outcomes related to fatigue and cognitive function suggest that Alixorexton may provide significant relief for patients suffering from narcolepsy and idiopathic hypersomnia [3] Group 2 - Alkermes is a global biopharmaceutical company focused on developing and commercializing treatments for complex psychiatric and neurological disorders, including addiction, schizophrenia, and bipolar disorder [4] - The company has a diverse portfolio of marketed products and a pipeline of investigational drug candidates, emphasizing its commitment to neuroscience innovation [4]